Merck & Company, Inc. (MRK): Valuation
TTM figures as of June 30, 2026
Merck & Company, Inc. trades at 111.9 times trailing earnings and a 4.52% free-cash-flow yield. On P/E that is higher than 90% of its own month-end history back to 2009. The Healthcare median P/E is 22.9.
Earnings yield 0.89%. Shareholder yield 3.52%. Piotroski F-score 4 of 9. Net debt $46.8B.
207 month-end valuation observations are on file, starting June 2009.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is MRK cheap versus its own history?
Merck & Company, Inc. trades at 111.9 times trailing earnings and a 4.52% free-cash-flow yield. On P/E that is higher than 90% of its own month-end history back to 2009. The Healthcare median P/E is 22.9.
What is MRK's free-cash-flow yield?
Merck & Company, Inc. currently yields 4.52% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.